New targeted drug takes on hard-to-treat pancreatic cancer
NCT ID NCT07262567
First seen Jan 10, 2026 · Last updated May 16, 2026 · Updated 22 times
Summary
This study tests a new drug, GFH375, against standard chemotherapy in 320 people with advanced pancreatic cancer that has a specific genetic change (KRAS G12D). Participants must have already tried at least one prior treatment. The goal is to see if GFH375 helps people live longer and slows cancer growth better than chemotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.